• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=23603901).
  

PubMed=23603901; DOI=10.1101/gad.217778.113; PMCID=PMC3656328
Chan K.-M., Fang D., Gan H.-Y., Hashizume R., Yu C.-H., Schroeder M., Gupta N., Mueller S., James C.D., Jenkins R.B., Sarkaria J., Zhang Z.-G.
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
Genes Dev. 27:985-990(2013)

PubMed=24305702; DOI=10.1093/neuonc/not220; PMCID=PMC3922515
Mueller S., Hashizume R., Yang X.-D., Kolkowitz I., Olow A.K., Phillips J.J., Smirnov I., Tom M.W., Prados M.D., James C.D., Berger M.S., Gupta N., Haas-Kogan D.A.
Targeting Wee1 for the treatment of pediatric high-grade gliomas.
Neuro-oncol. 16:352-360(2014)

PubMed=25401693; DOI=10.1038/nm.3716; PMCID=PMC4257862
Hashizume R., Andor N., Ihara Y., Lerner R., Gan H.-Y., Chen X.-Y., Fang D., Huang X., Tom M.W., Ngo V., Solomon D.A., Mueller S., Paris P.L., Zhang Z.-G., Petritsch C.K., Gupta N., Waldman T.A., James C.D.
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.
Nat. Med. 20:1394-1396(2014)

PubMed=29760046; DOI=10.1158/0008-5472.CAN-17-3691; PMCID=PMC6294442
Pal S., Kozono D., Yang X.-D., Fendler W., Fitts W., Ni J., Alberta J.A., Zhao J., Liu K.X., Bian J., Truffaux N., Weiss W.A., Resnick A.C., Bandopadhayay P., Ligon K.L., DuBois S.G., Mueller S., Chowdhury D., Haas-Kogan D.A.
Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas.
Cancer Res. 78:4007-4021(2018)

PubMed=34078608; DOI=10.1126/sciadv.abg4126; PMCID=PMC10166578
Wang J., Huang T.Y.-T., Hou Y., Bartom E.T., Lu X.-Y., Shilatifard A., Yue F., Saratsis A.M.
Epigenomic landscape and 3D genome structure in pediatric high-grade glioma.
Sci. Adv. 7:eabg4126.1-eabg4126.16(2021)